ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BIVI / options
KTTA (40) HIND (29) JAGX (28) BOLT (37) ⌘ Pro Terminal β†’

BioVie Inc. (Class A) (BIVI) Options Positioning, Max Pain & Unusual Sweeps

$1.37 -4.20% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.36

BioVie Inc. (Class A) (BIVI) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $12.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BIVI Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BIVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, BioVie Inc. (Class A) (NASDAQ: BIVI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.37 (-4.20% 1D, market cap $12.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BIVI ranks #738 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BIVI compare to KTTA and HIND in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIVI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, KTTA (Pasithea Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and HIND (Vyome Holdings Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BIVI leads on earnings multiple (N/A) while BIVI leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BIVI?
β–Ό

Per BIVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001580149), BioVie Inc. (Class A) generated $50.6M in revenue (-43.9% YoY), -$17.5M in net income, and -$19.0M in free cash flow against $22.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.36 (-0.95%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (4)Whales (5)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$4 Bull$1 Base$1 Bear
πŸ“¬ FREE BIVI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BIVI)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY BIVI SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime Γ— Technicals: 19% of 52W Range β€’ RSI-14 at 51.2 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
24
Grade E$1.20+3.3% Next Q
Q2 (-2Q)
27
Grade E$1.24+16.1% Next Q
Q3 (-1Q)
29
Grade E$1.44-4.9% Next Q
Current
32
Grade E$1.37-9.2% Hist 90D Ξ±
Trajectory: E (24) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BIVI Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BIVI currently carries a cautious 32/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.62) and Max Pain ($1.44) forces dealer call-delta covering toward $3.98.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BIVIβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBIVI Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BIVI)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BIVI.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BIVI)

  • βœ“Walkthrough of BIVI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BIVI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.35%⚑ TESTING RESISTANCE
2026-11-03O $1.38H $1.43L $1.37C $1.37VOL 105.8K
RES: $1.44SUP: $1.19SMA50: $1.62SMA200: $1.52
$4.00$3.14$2.28$1.41$0.55RES $1.44SUP $1.19$1.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BIVI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BIVI Butterfly Map β†’ + Track BIVI β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -43.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BIVI today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BIVI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BIVI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIVI)

Health Care Rank #738 of 1015 βš”οΈ KTTA vs BIVI Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BIVI vs. KTTA, HIND, JAGX, BOLT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BioVie Inc. (Class A) (BIVI) ranks #738 by composite RQD confidence (32/100, grade E) and #872 by equity capitalization ($12.4M). Within this direct 5-issuer industry benchmark cohort, BIVI leads on earnings valuation at N/A trailing P/E, while BIVI leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BIVI at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BIVI ACTIVE
BioVie Inc. (Class A)
E 32/100 β€” β€” -35.0% -4.20% $12.4M Benchmark Subject
KTTA
Pasithea Therapeutics Corp.
D- 40/100 β€” β€” -35.0% -0.59% $12.4M /ktta-vs-bivi β†’
HIND
Vyome Holdings Inc.
E 29/100 β€” 68.4% -35.0% -2.22% $12.6M /hind-vs-bivi β†’
JAGX
Jaguar Health Inc.
E 28/100 β€” 67.2% -35.0% -45.43% $12.6M /jagx-vs-bivi β†’
BOLT
Bolt Biotherapeutics Inc.
D- 37/100 β€” β€” -35.0% -5.31% $12.7M /bolt-vs-bivi β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-06-30 β€’ CIK 0001580149 β†—

In its most recent audited fiscal period (FY2025, filed 2025-06-30), BioVie Inc. (Class A) (BIVI) reported GAAP revenue of $50.6M (-43.9% vs. FY2024 revenue of $90.1M , and -59.9% cumulative change since FY2023) , GAAP net income of -$17.5M, operating cash flow of -$19.0M, and free cash flow of -$19.0M (+31.9% YoY). On the balance sheet, BIVI closed FY2025 with $22.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $50.6M -$17.5M -$19.0M -$19.0M $22.5M β€”
FY2024 (FY) 2024-06-30 $90.1M -$32.1M -$27.9M -$27.9M $25.7M β€”
FY2023 (FY) 2023-06-30 $126.2M -$50.3M -$40.3M -$40.3M β€” β€”

3. BIVI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BIVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BioVie Inc. (Class A) (NASDAQ: BIVI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.37 (-4.20% 1D, market cap $12.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BIVI ranks #738 in composite RQD confidence.

How does BIVI compare to KTTA and HIND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIVI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, KTTA (Pasithea Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and HIND (Vyome Holdings Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BIVI leads on earnings multiple (N/A) while BIVI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BIVI?

Per BIVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001580149), BioVie Inc. (Class A) generated $50.6M in revenue (-43.9% YoY), -$17.5M in net income, and -$19.0M in free cash flow against $22.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BIVI trading relative to its 50-day, 200-day, and 52-week technical levels?

BIVI last traded at $1.37 (-4.20% on volume of 120,891 shares), positioning the stock -15.43% below its 50-day simple moving average ($1.62) and -9.87% below its 200-day simple moving average ($1.52). Across its 52-week range of $0.82 to $3.79, BIVI sits at the 18.5% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.20 to $1.54).

Direct Sub-Reports: BIVI RQD Cockpit BIVI 12M Forecast BIVI Earnings & Move BIVI Dividends & DRIP BIVI Insiders & 13F BIVI Whale Options BIVI Profit Sankey BIVI News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

BIVI β€” BioVie Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

BioVie Inc. (Class A) (BIVI) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.37 (-4.20% 1D, market capitalization $12.4M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BioVie Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Reported revenue is β€” across all listed periods . Market capitalization is $12.0M per the market data section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), BioVie Inc. (Class A) (BIVI) reported $50.6M in annual revenue (up from $90.1M in FY2024, -43.9% YoY) and -$17.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($126.2M revenue, -$50.3M net income) through FY2025, BIVI scaled operating cash flow to -$19.0M and free cash flow to -$19.0M, backed by $22.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.82 – $3.79 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and bottlenecks are therefore β€” A prospective investor should note that the graph provides no basis for identifying second-order ripples through suppliers or customers.

  • Key Question #1: Can BIVI sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $50.6M and free cash flow of -$19.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BIVI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BIVI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioVie Inc. (Class A) (BIVI) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BIVI Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BIVI Bull vs. Bear Conversation Board β€” What's Your Call at $1.37?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BIVI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BIVI:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $1.73 (+21.0%)
πŸ“Œ Pinned Debate

Balance-sheet pillar scores 10 of 20 with Altman Z of 2.5, and reported cash of $20.5M in FY 2025 provides a tangible funding base.

Balance-sheet pillar scores 10 of 20 with Altman Z of 2.5, and reported cash of $20.5M in FY 2025 provides a tangible funding base.. When you look under the hood at BIVI, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $3.79. My 12M target is $1.73.

SectorRotator πŸ‚ BULL

@DeepValue_CFA Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.43 and keeping dry powder in case we test $1.33.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.13 (-21.0%)
Spot @ $1.43

ROIC of -35%, zero revenue across all periods, and FCF of -$19.0M in FY 2025 against $20.5M cash point to a limited cash runway and a S

Fading this rally in BIVI at $1.43. ROIC of -35%, zero revenue across all periods, and FCF of -$19.0M in FY 2025 against $20.5M cash point to a limited cash runway and a Strong Sell RQD grade.. With a beta of 1.0 and the stock sitting at $1.43 (52-wk range $0.82–$3.79), the easy multiple expansion is already priced in.

LIVE TAPE